Last updated: August 18, 2026

Examiner: ABDALHAMEED, MANAHIL MIRGHANI ALI

Tech Center 1600 • Art Units: 1622 1625 1629

This examiner grants 50% of resolved cases

Performance Statistics

50.4%

Allow Rate

-9.6% vs TC avg

187

Total Applications

+40.1%

Interview Lift

1021

Avg Prosecution Days

Based on 141 resolved cases, 2023–2026

2.9%

§101 Eligibility

17.4%

§102 Novelty

40.4%

§103 Obviousness

20.0%

§112 Clarity

App #	Title	Status	Assignee
18726838	PROCESS FOR ISOLATING 2,4-BIS-(2,4-DIHYDROXYPHENYL)-6-(4-METHOXYPHENYL)-1,3,5-TRIAZINE (DIOPAT)	Non-Final OA	BASF SE
18282424	NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE	Non-Final OA	The Regents of the University of Michigan
17801486	TREATMENT FOR CHEMOBRAIN	Final Rejection	YALE UNIVERSITY
18559492	DEUTERATED IRAK DEGRADERS AND USES THEREOF	Non-Final OA	Kymera Therapeutics, Inc.
18017767	COMPOSITIONS AND METHODS FOR LEVODOPA DELIVERY	Final Rejection	Purdue Pharma L.P.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.